Immunic reports Q3 2023 net loss $22.8M; positive CALLIPER interim NfL data

IMMUNIC, INC.

2023-Q3 EPS reported -$1.63

Net loss of $22.8M ($0.51/sh) for Q3 2023 vs $21.2M ($0.69/sh) in Q3 2022.
Cash and investments of $59.7M as of Sep 30, 2023; expected runway into Sep 2024.
Phase 2 CALLIPER trial in progressive MS met interim biomarker endpoint: serum NfL improved vs placebo across all subtypes.
Received US patent notice of allowance for vidofludimus calcium in relapsing MS, extending protection to 2041.
CALLIPER enrollment completed (467 pts); top-line data expected April 2025; ENSURE interim futility late 2024.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.4

IMMUNIC, INC. reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 14, 2023, Immunic, Inc. (the “Company”) issued a press release, a copy of which is furnished herewith as Exhibit 99.1, announcing the Company’s financial results for the quarter ended September 30, 2023 and providing a corporate update

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

IMMUNIC, INC. filing history →

Source: SEC EDGAR

accession 0001193805-23-001486

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.